EUVIMEDEUVIMED entdecken
Crossref

A tumor suppressor function for prosurvival BCL-2 proteins in the thymus

Meng-Xiao Luo, Antonia Policheni, Feng Yan, Stephanie Grabow, Kelin Zhao, Nadia M Davidson, Charis E Teh, Andreas Strasser, Daniel H D Gray

Genes & Development · 12.11.2026

DOI: 10.1101/gad.353558.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes & Development, online erschienen am 12.11.2026. Verfasst von Meng-Xiao Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. Gefördert von: National Health and Medical Research Council, NHMRC Fellowship, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Defective cell competition has been linked to tumorigenesis in various cancers, including acute lymphoblastic leukemia (T-ALL), but the underlying mechanisms remain unclear. In the thymus, we found marked elevation in the amount of prosurvival BCL-2 protein in “new” progenitors competing with “old” counterparts, suggesting an apoptotic mechanism. However, in a thymic transplant model of disrupted cell competition, Bcl2 deletion paradoxically accelerated the onset of leukemia resembling T-ALL. Mechanistically, the loss of BCL-2 did not alter competitive outcomes but induced heightened apoptosis and increased IL-7-driven compensatory proliferation in the surviving progenitors. This elevated cell turnover accelerated the acquisition of oncogenic mutations but did not change the mutational burden or landscape of T-ALL. More broadly, we found that even modest reduction in the related prosurvival proteins, MCL-1 or BCL-XL, also accelerated T-ALL-like disease in the transplant model. In a separate setting, conditional ablation of Mcl1 early in thymic lymphopoiesis caused profound thymocyte loss, elevated progenitor proliferation and spontaneous T-ALL. These findings define a tumor-suppressive function for BCL-2 family proteins in settings of defective cell competition, with important implications for the therapeutic use of BH3 mimetics in cancer.

Schlagwörter

Stichwörter der Autor:innen

BCL-2apoptosiscell competitionleukemiathymus

Autor:innen und Institutionen

  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
  • Department of Medical Biology, The University of Melbourne, Victoria 3052, Australia.
  • Amgen Inc., Thousand Oaks, California 91320, USA.
  • RayzeBio, San Diego, California 92121, USA.
  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; dgray@wehi.edu.au.

Förderung

  • National Health and Medical Research Council
  • NHMRC Fellowship
  • NHMRC
  • Leukemia and Lymphoma Society-Specialized Center of Research
  • Cancer Council of Victoria
  • Leukemia Foundation Postgraduate Research Scholarship
  • Postdoctoral Cancer Research Fellowship
  • Cancer Council

Zitieren

APA

Luo, M. X., Policheni, A., Yan, F., Grabow, S., Zhao, K., Davidson, N. M., Teh, C. E., Strasser, A., & Gray, D. H. D. (2026). A tumor suppressor function for prosurvival BCL-2 proteins in the thymus. Genes & Development. https://doi.org/10.1101/gad.353558.125

Vancouver

Luo MX, Policheni A, Yan F, Grabow S, Zhao K, Davidson NM, et al. A tumor suppressor function for prosurvival BCL-2 proteins in the thymus. Genes & Development. 2026. doi:10.1101/gad.353558.125

BibTeX
@article{Luo2026,
  author = {Luo, Meng-Xiao and Policheni, Antonia and Yan, Feng and Grabow, Stephanie and Zhao, Kelin and Davidson, Nadia M and Teh, Charis E and Strasser, Andreas and Gray, Daniel H D},
  title = {A tumor suppressor function for prosurvival BCL-2 proteins in the thymus},
  journal = {Genes & Development},
  year = {2026},
  doi = {10.1101/gad.353558.125}
}
Kostenlos starten →